Provided by Tiger Trade Technology Pte. Ltd.

Mineralys Therapeutics, Inc.

29.30
-1.2000-3.93%
Post-market: 29.300.00000.00%19:30 EDT
Volume:763.76K
Turnover:22.66M
Market Cap:2.58B
PE:-6.70
High:30.57
Open:30.04
Low:29.20
Close:30.50
52wk High:47.65
52wk Low:22.30
Shares:88.16M
Float Shares:66.03M
Volume Ratio:0.44
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3763
EPS(LYR):-2.2900
ROE:-80.88%
ROA:-46.18%
PB:4.69
PE(LYR):-12.79

Loading ...

Bayer's Key Pharma Products Face Competitive Risk -- Market Talk

Dow Jones
·
May 29

Will Phase 3 Launch-HTN Success and Conference Spotlight Change Mineralys Therapeutics' (MLYS) Narrative?

Simply Wall St.
·
May 29

Mineralys Therapeutics to Present at Jefferies Global Healthcare Conference

Reuters
·
May 27

Mineralys Therapeutics shareholders approve Ernst & Young as auditor

Reuters
·
May 23

Mineralys CMO David Malcom Rodman disposes of 417 shares for $11,491.35

Reuters
·
May 20

Guggenheim Keeps Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

TIPRANKS
·
May 19

Mineralys presents Phase 3 Launch-HTN lorundrostat data in hypertension, CKD at ESH 2026

Reuters
·
May 19

BRIEF-Mineralys Therapeutics Announces Presentation Of New Data From The Late-Stage Launch-Htn Trial Of Lorundrostat

Reuters
·
May 19

Mineralys Therapeutics Announces Presentation of New Data From the Phase 3 Launch-Htn Trial of Lorundrostat at the 35TH European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

THOMSON REUTERS
·
May 19

Mineralys CMO David Malcom Rodman disposes of shares worth $648,330.57

Reuters
·
May 14

Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Context Therapeutics (CNTX)

TIPRANKS
·
May 07

Mineralys Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Earnings Flash (MLYS) Mineralys Therapeutics Posts Q1 EPS -$0.47, vs. FactSet Est of -$0.47

MT Newswires Live
·
May 07

Mineralys Therapeutics Q1 EPS USD -0.47

THOMSON REUTERS
·
May 07

Mineralys Q1 FY26 net loss narrows to $39.3 million; G&A expenses climb to $21 million

Reuters
·
May 07

Mineralys Therapeutics Inc - FDA Accepts Nda for Lorundrostat in Hypertension With Pdufa Date December 22, 2026

THOMSON REUTERS
·
May 07

BRIEF-Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
May 06

Mineralys grants inducement equity awards totaling 52,080 shares to two new hires

Reuters
·
May 06

Mineralys Therapeutics to join Bank of America Securities Health Care Conference fireside chat

Reuters
·
May 05

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

GlobeNewswire
·
May 05